We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Protein Overexpression Underlies Inflammatory Skin Diseases

By Biotechdaily staff writers
Posted on 17 May 2006
Researchers working with a line of genetically engineered mice found that a mutation that triggers over-production of the skin protein connexin 26 caused defects in the protective properties of the skin, which resulted in inflammatory skin diseases such as eczema and psoriasis.

Investigators at the [U.S.] National Institutes of Health (Bethesda, MD, USA) genetically engineered a line of mice that did not express the gene for the transcription factor Kruppel-like factor 4 (Klf4). More...
These animals displayed severe defects in skin development as well as overexpression of the of the gap junction protein connexin 26 (Cx26). This protein is required by the embryo during development and by mature individuals during wound healing but is otherwise inactive.

The current work, which was published in the May 2006 issue of the Journal of Clinical Investigation, showed that constant activation of Cx26 interfered with skin development in young animals and skin maintenance and healing in older ones. Skin conditions resembling human eczema and psoriasis appeared due to infiltration of the skin by hyperactive immune cells.

"Hopefully, this will help us understand the complex genetics of psoriasis,” said senior author Dr. Julia A. Segre, an investigator at the National Institutes of Health. "Previous genetic studies have focused on the genes that regulate immune response. We are now examining the effect of genes that are involved in both regulating the growth of skin cells and signaling to the immune cells. The skin cells grow so fast that they fail to make a normal barrier, and the body is stimulating the immune response because of material (chemicals and allergens) coming through the barrier.”



Related Links:
[U.S.] National Institutes of Health

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.